89 related articles for article (PubMed ID: 15364449)
41. Therapeutic human papillomavirus vaccines: current clinical trials and future directions.
Hung CF; Ma B; Monie A; Tsen SW; Wu TC
Expert Opin Biol Ther; 2008 Apr; 8(4):421-39. PubMed ID: 18352847
[TBL] [Abstract][Full Text] [Related]
42. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
Park YS; Lee JH; Hung CF; Wu TC; Kim TW
Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494
[TBL] [Abstract][Full Text] [Related]
43. Calreticulin requires an ancillary adjuvant for the induction of efficient cytotoxic T cell responses.
Bak SP; Amiel E; Walters JJ; Berwin B
Mol Immunol; 2008 Mar; 45(5):1414-23. PubMed ID: 17936359
[TBL] [Abstract][Full Text] [Related]
44. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
[TBL] [Abstract][Full Text] [Related]
45. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
[TBL] [Abstract][Full Text] [Related]
46. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.
Cheng WF; Hung CF; Chai CY; Hsu KF; He L; Ling M; Wu TC
J Clin Invest; 2001 Sep; 108(5):669-78. PubMed ID: 11544272
[TBL] [Abstract][Full Text] [Related]
47. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
Chen CH; Wang TL; Ji H; Hung CF; Pardoll DM; Cheng WF; Ling M; Wu TC
Gene Ther; 2001 Jan; 8(2):128-38. PubMed ID: 11313782
[TBL] [Abstract][Full Text] [Related]
48. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity.
Cheng WF; Lee CN; Su YN; Chai CY; Chang MC; Polo JM; Hung CF; Wu TC; Hsieh CY; Chen CA
Cancer Gene Ther; 2006 Sep; 13(9):873-85. PubMed ID: 16645621
[TBL] [Abstract][Full Text] [Related]
49. Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin.
Lin CT; Chang TC; Chao A; Dzeng E; Soong YK; Hung CF; Lai CH
J Biomed Sci; 2005; 12(2):279-87. PubMed ID: 15918000
[TBL] [Abstract][Full Text] [Related]
50. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
[TBL] [Abstract][Full Text] [Related]
51. Poxviruses as vaccine vectors.
Pastoret PP; Vanderplasschen A
Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):343-55. PubMed ID: 12818621
[TBL] [Abstract][Full Text] [Related]
52. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.
Adams M; Borysiewicz L; Fiander A; Man S; Jasani B; Navabi H; Lipetz C; Evans AS; Mason M
Vaccine; 2001 Mar; 19(17-19):2549-56. PubMed ID: 11257391
[TBL] [Abstract][Full Text] [Related]
53. Technology evaluation: TG-1031, Transgene SA.
Doehn C; Jocham D
Curr Opin Mol Ther; 2000 Feb; 2(1):106-11. PubMed ID: 11249647
[TBL] [Abstract][Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
